InflaRx, which is developing an antibody for rare autoimmune and inflammatory diseases, raised $100 million by offering 6.7 million shares at $15, the midpoint of the $14 to $16 range. Insiders are buying $40 million (40% of the deal) on the offering. InflaRx plans to list on the Nasdaq under the symbol IFRX. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as lead managers on the deal.
